Neoleukin Therapeutics (NASDAQ:NLTX) Trading 2.1% Higher - Still a Buy?

Key Points

• Shares rose 2.1% intraday to $20.91 (high $21.10) with volume up 41% to 70,455 shares, trading above the 50‑day moving average ($19.81) but below the 200‑day ($21.74); the company has a market cap of about $196.5M and a negative P/E (-6.72), consistent with a clinical‑stage biopharma.
• Neoleukin is a clinical‑stage biotech using computational protein engineering to create de novo cytokine mimetics, and its lead candidate NL‑201 aims to engage IL‑2/IL‑15 receptors to boost anti‑tumor immune responses while reducing toxicity from natural cytokines.

Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) traded up 2.1% on Wednesday . The stock traded as high as $21.10 and last traded at $20.91. 70,455 shares were traded during mid-day trading, an increase of 41% from the average session volume of 50,104 shares. The stock had previously closed at $20.47.

Neoleukin Therapeutics Price Performance

The firm has a fifty day moving average of $19.81 and a two-hundred day moving average of $21.74. The stock has a market capitalization of $196.51 million, a P/E ratio of -6.72 and a beta of 1.11.

Neoleukin Therapeutics Company Profile

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company's lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.